In vitro evaluation of prestorage pooled leukoreduced whole blood–derived platelets stored for up to 7 days

Heddle, Nancy M.; Barty, Rebecca; Sigouin, Christopher; Boye, D.M.; Nelson, E. J.; Blajchman, Morris A.; Kelton, John G.

doi:10.1111/j.1537-2995.2005.04234.x

Cited by 23 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By current US Food and Drug Administration (FDA) rule, whole blood-derived platelets must be pooled prior to issue as opposed to prestorage. [7][8][9] Individually culturing multiple concentrates comprising a single platelet dose would be prohibitively cumbersome and expensive, so for whole blood-derived platelets, non-licensed, non-culture methods such as pH and glucose testing (using a dipstick or automated analyzer) and Gram staining are performed. However, the sensitivity and specificity of these non-culture methods is inferior to culture-based methods.…”

Section: Screening Platelets For Bacteriamentioning

confidence: 99%

Platelets: Testing, Dosing and the Storage Lesion—Recent Advances

Kaufman¹

2006

Hematology

View full text Add to dashboard Cite

The demand for platelet transfusions continues to grow. Several complementary approaches that may help meet this demand in the future are reviewed. First, platelet bacterial testing is beginning to allow the extension of platelet storage beyond 5 days. Studies are also underway aimed at better preserving viability and function during ex vivo platelet storage: additive solutions and other approaches are being developed to try to negate the "platelet storage lesion." Finally, new approaches to dosing platelets may help extend the limited supply.

show abstract

Section: Screening Platelets For Bacteriamentioning

confidence: 99%

Platelets: Testing, Dosing and the Storage Lesion—Recent Advances

Kaufman¹

2006

Hematology

View full text Add to dashboard Cite

show abstract

“…However, while constructing homogenous pools confers this advantage, we have found that this pooling strategy may not be practical. For example, in infectious-disease screening, individual samples of blood or sera have a finite shelf life [21] so one can not simply wait for other homogenous individuals to enter the study. In drug discovery, Remlinger et al [7] argue that constructing homogenous pools may be suboptimal if the goal is to identify individual compounds which are biologically active.…”

Section: Introductionmentioning

confidence: 99%

Bias, efficiency, and agreement for group-testing regression models

Bilder

Tebbs

2009

Journal of Statistical Computation and Simulation

View full text Add to dashboard Cite

Group testing involves pooling individual items together and testing them simultaneously for a rare binary trait. Whether the goal is to estimate the prevalence of the trait or to identify those individuals that possess it, group testing can provide substantial benefits when compared to testing subjects individually. Recently, group-testing regression models have been proposed as a way to incorporate covariates when estimating trait prevalence. In this paper, we examine these models by comparing fits obtained from individual and group testing samples. Relative bias and efficiency measures are used to assess the accuracy and precision of the resulting estimates using different grouping strategies. We also investigate the agreement of individual and group-testing regression estimates for various grouping strategies and the effects of group size selection. Depending on how groups are formed, our results show that group-testing regression models can perform very well when compared to the analogous models based on individual observations. However, different grouping strategies can provide very different results in finite samples.

show abstract

“…Although bioassays for assessment of functional TGF-b (Randall et al, 1993) and determination of TGF-b concentrations (Danielpour, 1993;Grainger et al 1995;Meager, 1991;Phillips et al, 1995;Szymkowiak et al, 1995) have been extensively described, substantially different ranges given for the concentration of TGF-b in blood, and several different recommendations for pre-analytical sample handling are reported (Heddle et al, 2005;Tylman et al, 2006;Walther et al, 2009). In current conventional assays, blood collection methods, sample handling and temperature storage proved to crucially impact the outcome of the assays (van Waarde et al, 1997;Wakefield et al, 1995) and to be in fact key factors for TGF-b levels variability to the extent of invalidating the accuracy of correlative studies where TGF-b is used as a prognostic biomarker for clinical outcome and disease progression (Pircher et al, 1986;Wakefield et al, 1988).…”

Section: Discussionmentioning

confidence: 99%

Development of a novel multiplexed assay for quantification of transforming growth factor-β(TGF-β)

Pellicciotta¹,

Marciscano²,

Hardee³

et al. 2015

Growth Factors

View full text Add to dashboard Cite

Changes in activity or levels of transforming growth factor-β (TGF-β) are associated with a variety of diseases; however, measurement of TGF-β in biological fluids is highly variable. TGF-β is biologically inert when associated with its latency-associated peptide (LAP). Most available immunoassays require exogenous activation by acid/heat to release TGF-β from the latent complex. We developed a novel electrochemiluminescence-based multiplexed assay on the MesoScale Discovery® platform that eliminates artificial activation, simultaneously measures both active TGF-β1 and LAP1 and includes an internal control for platelet-derived TGF-β contamination in blood specimens. We optimized this assay to evaluate plasma levels as a function of activation type and clinical specimen preparation. We determined that breast cancer patients' plasma have higher levels of circulating latent TGF-β (LTGF-β) as measured by LAP1 than healthy volunteers (p < 0.0001). This assay provides a robust tool for correlative studies of LTGF-β levels with disease, treatment outcomes and toxicity with a broad clinical applicability.

show abstract

In vitro evaluation of prestorage pooled leukoreduced whole blood–derived platelets stored for up to 7 days

Abstract: These results suggest that prestorage pooled PLTs can be stored for up to 7 days; however, studies are needed to ensure that the clinical benefit of PLTs stored as a pool is not inferior to those stored individually.

Cited by 23 publications

References 33 publications

Platelets: Testing, Dosing and the Storage Lesion—Recent Advances

Platelets: Testing, Dosing and the Storage Lesion—Recent Advances

Bias, efficiency, and agreement for group-testing regression models

Development of a novel multiplexed assay for quantification of transforming growth factor-β(TGF-β)

Contact Info

Product

Resources

About